Search Videos and More

Showing 1 - 12 of 27 results

Previous| 1 | 2 | 3 |Next


Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds News

Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds

Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.
Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds News

Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds

A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.
New Insights into Immunotherapy Targets for Pancreatic Cancer News

New Insights into Immunotherapy Targets for Pancreatic Cancer

Cancer research often focuses on gene mutations in the parts of the human genome that produce cellular machinery called proteins. But the rest of the genome — sometimes called the “dark genome” — can also play a role.  
FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research News

FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research

FDA decision establishes cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors
Blood Test Could Guide Use of Anti-Inflammatory Drug Celecoxib to Reduce Risk of Colon Cancer Recurrence News

Blood Test Could Guide Use of Anti-Inflammatory Drug Celecoxib to Reduce Risk of Colon Cancer Recurrence

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit from adding of celecoxib, to post surgery treatment.
High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer News

High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer

SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial of vitamin D combined with standard chemotherapy plus bevacizumab in patients with previously untreated metastatic colorectal cancer.
Early Action, Better Outcomes: Transforming Cancer Prevention News

Early Action, Better Outcomes: Transforming Cancer Prevention

For more than 100 years, health advocates have spread the message that, with cancer, patience is not a virtue.
In a First, Immune Checkpoint Inhibitors Show Effectiveness in Metastatic Colorectal Cancer News

In a First, Immune Checkpoint Inhibitors Show Effectiveness in Metastatic Colorectal Cancer

In trial after clinical trial, metastatic colorectal cancer has been largely undeterred by immune checkpoint inhibitors. 
Live Cell Imaging IDs Bad Actors in Cancer and Finds Possible Ways to Defeat Them News

Live Cell Imaging IDs Bad Actors in Cancer and Finds Possible Ways to Defeat Them

Most forms of chemotherapy are designed to kill cancer cells. But some cancer cells survive. Those that do can cause the cancer to relapse.
New Targeted Treatments Emerge for Gastric and Esophageal Cancer News

New Targeted Treatments Emerge for Gastric and Esophageal Cancer

For years, patients with advanced forms of gastric and esophageal cancer have had relatively few treatment options.
New Research from Dana-Farber Brigham Cancer Center and Memorial Sloan Kettering Cancer Center Finds that Radiation Can Be Safely Omitted in Select Patients with Locally Advanced Rectal Cancer News

New Research from Dana-Farber Brigham Cancer Center and Memorial Sloan Kettering Cancer Center Finds that Radiation Can Be Safely Omitted in Select Patients with Locally Advanced Rectal Cancer

New data led by researchers at Dana-Farber Brigham Cancer Center and Memorial Sloan Kettering Cancer Center (MSK) and featured in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting press program and simultaneously published in?The New England Journal of Medicine (NEJM)?and the Journal of Clinical Oncology today indicates that some patients with locally advanced rectal cancer with tumors that respond to chemotherapy can safely forego radiation before surgery.
Clinical Trial Shows That Adding Bevacizumab to Targeted Drug and Chemotherapy Produces Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma News

Clinical Trial Shows That Adding Bevacizumab to Targeted Drug and Chemotherapy Produces Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma

Long-term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma

Showing 1 - 12 of 27 results

Previous| 1 | 2 | 3 |Next